Innoviva Inc (INVA)
15.79
+0.44
(+2.87%)
USD |
NASDAQ |
May 31, 16:00
15.79
0.00 (0.00%)
After-Hours: 20:00
Innoviva Enterprise Value: 1.254B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 1.254B |
| May 30, 2024 | 1.227B |
| May 29, 2024 | 1.226B |
| May 28, 2024 | 1.239B |
| May 24, 2024 | 1.254B |
| May 23, 2024 | 1.254B |
| May 22, 2024 | 1.273B |
| May 21, 2024 | 1.277B |
| May 20, 2024 | 1.276B |
| May 17, 2024 | 1.266B |
| May 16, 2024 | 1.266B |
| May 15, 2024 | 1.258B |
| May 14, 2024 | 1.274B |
| May 13, 2024 | 1.279B |
| May 10, 2024 | 1.243B |
| May 09, 2024 | 1.223B |
| May 08, 2024 | 1.240B |
| May 07, 2024 | 1.238B |
| May 06, 2024 | 1.233B |
| May 03, 2024 | 1.218B |
| May 02, 2024 | 1.228B |
| May 01, 2024 | 1.219B |
| April 30, 2024 | 1.212B |
| April 29, 2024 | 1.240B |
| April 26, 2024 | 1.222B |
| Date | Value |
|---|---|
| April 25, 2024 | 1.206B |
| April 24, 2024 | 1.216B |
| April 23, 2024 | 1.217B |
| April 22, 2024 | 1.202B |
| April 19, 2024 | 1.203B |
| April 18, 2024 | 1.187B |
| April 17, 2024 | 1.178B |
| April 16, 2024 | 1.177B |
| April 15, 2024 | 1.173B |
| April 12, 2024 | 1.187B |
| April 11, 2024 | 1.192B |
| April 10, 2024 | 1.185B |
| April 09, 2024 | 1.193B |
| April 08, 2024 | 1.193B |
| April 05, 2024 | 1.189B |
| April 04, 2024 | 1.189B |
| April 03, 2024 | 1.198B |
| April 02, 2024 | 1.198B |
| April 01, 2024 | 1.224B |
| March 31, 2024 | 1.225B |
| March 28, 2024 | 1.216B |
| March 27, 2024 | 1.219B |
| March 26, 2024 | 1.200B |
| March 25, 2024 | 1.207B |
| March 22, 2024 | 1.207B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
876.81M
Minimum
Mar 18 2020
1.871B
Maximum
Apr 08 2022
1.316B
Average
1.320B
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 4.387M |
| Palatin Technologies Inc | 19.03M |
| iBio Inc | 28.91M |
| Theriva Biologics Inc | -10.98M |
| Oragenics Inc | 8.699M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 36.53M |
| Revenue (Quarterly) | 77.50M |
| Total Expenses (Quarterly) | 51.69M |
| EPS Diluted (Quarterly) | 0.46 |
| Gross Profit Margin (Quarterly) | 85.84% |
| Profit Margin (Quarterly) | 47.14% |
| Earnings Yield | 14.06% |
| Operating Earnings Yield | 8.66% |
| Normalized Earnings Yield | 14.12 |